A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2 | bioRxiv
bnAbs for HIV Prevention - IAVI
Non-neutralizing antibodies and vaccine-induced protection against HIV | Future HIV Therapy
Heterophilic Blocking Reagents (HAMA Blocker) - dianova
Frontiers | Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies
Broadly neutralizing antibodies to prevent HIV-1 | Science
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: Trends in Immunology
Measuring Neutralizing Ability to SARS-CoV-2 Variant Spike Proteins | Bio-Techne
Passive antibody therapy in COVID-19 | Nature Reviews Immunology
Recombinant Mouse IgG Antibody
Reversible blocking of antibodies using bivalent peptide–DNA conjugates allows protease-activatable targeting - Chemical Science (RSC Publishing)
Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy | ACS Central Science
Turning antibodies off and on again using a covalently tethered blocking peptide | Communications Biology
Developing reagents for SARS-CoV-2 neutralizing antibody detection
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Frontiers | Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
SARS-CoV-2 Neutralizing Antibody ELISA Kit - Creative Diagnostics
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection - ScienceDirect
Peptide Blocking: Novus Biologicals
What is antibody therapy?
Cancers | Free Full-Text | CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
What are neutralizing antibodies – the immune system's superheroes - Fluidic Analytics
Anti-mCD25 | PC-61.5.3 & 7D4| InvivoGen
COVID-19 Neutralizing Antibody Test | anptech
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants | NEJM
